专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08906420B2 Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix 有权
标题翻译：在侵蚀基质中包含一种或多种富马酸酯的药物制剂
公开(公告)号：US08906420B2
公开(公告)日：2014-12-09
申请号：US13143498
申请日：2010-01-08
申请人： Henrik Nilsson , Roland Rupp
发明人： Henrik Nilsson , Roland Rupp
IPC分类号： A61K9/16 , A61K9/20 , A61K9/28 , A61K31/225 , A61K31/215
CPC分类号： A61K9/28 , A61K9/2054 , A61K9/2846 , A61K9/2866 , A61K9/2886 , A61K31/215 , A61K31/225
摘要： A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).
摘要翻译：包含含有一种或多种富马酸酯的腐蚀基质以及一种或多种速率控制剂的药物制剂，其中所述腐蚀基质的侵蚀允许所述富马酸酯的受控释放。

2. 发明授权

US08609616B2 Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions 失效
标题翻译：用于预防或治疗坏死性骨质状况的含锶化合物
公开(公告)号：US08609616B2
公开(公告)日：2013-12-17
申请号：US13182798
申请日：2011-07-14
申请人： Christian Hansen , Henrik Nilsson , Stephan Christgau , Henry G Bone, III
发明人： Christian Hansen , Henrik Nilsson , Stephan Christgau , Henry G Bone, III
IPC分类号： A61P19/08
CPC分类号： A61K33/24 , A61K31/28 , A61K31/56 , A61K31/57 , A61K31/663 , A61K45/06 , A61K2300/00
摘要： A method for the treatment and/or prophylaxis of an osteonecrotic bone disease in a mammal in need thereof, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia/osteonecrosis, Legg-Calve-Perthes disease and femoral head necrosis, the method comprising administering an effective dose of a strontium-containing compound (a) to the mammal. A method for the treatment and/or prophylaxis of an osteonecrotic bone disease, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia/osteonecrosis and femoral head necrosis, in a mammal who is to be or is treated with a therapeutic agent (b) known to or suspected of inducing apoptosis and/or necrosis of bone cells, the method comprising administering a strontium-containing compound (a) in combination with (b).
摘要翻译：用于治疗和/或预防有需要的哺乳动物中的骨坏死性骨病的方法，例如特发性或继发性骨坏死，无血管性骨坏死，糖皮质激素诱导的骨缺血/骨坏死，Legg-Calve-Perthes疾病和股骨头坏死，所述方法包括向哺乳动物施用有效剂量的含锶化合物（a）。用于治疗和/或预防将要或被治疗的哺乳动物中的骨坏死性骨病，例如特发性或继发性骨坏死，无血管性骨坏死，糖皮质激素诱导的骨缺血/骨坏死和股骨头坏死的方法具有已知或怀疑诱导骨细胞凋亡和/或坏死的治疗剂（b），该方法包括与（b）组合施用含锶化合物（a）。

3. 发明申请

US20110231051A1 USE OF SUSPENSION INFORMATION IN TIRE PRESSURE DEVIATION DETECTION FOR A VEHICLE TIRE 有权
标题翻译：悬挂信息在轮胎胎压偏差检测中的应用
公开(公告)号：US20110231051A1
公开(公告)日：2011-09-22
申请号：US12531689
申请日：2007-03-16
申请人： Markus Gerdin , Henrik Nilsson , Tony Gustafsson , Mots Löfgren
发明人： Markus Gerdin , Henrik Nilsson , Tony Gustafsson , Mots Löfgren
IPC分类号： B60C23/00
CPC分类号： B60C23/061 , B60C23/062
摘要： A method, system and computer program product for detecting a tire pressure deviation in a tire of a vehicle by determining tire pressure indicating data indicative of a tire pressure condition of the tire and determining tire pressure deviation data indicative of a tire pressure deviation in the tire.
摘要翻译：一种方法，系统和计算机程序产品，用于通过确定表示轮胎的轮胎压力状况的轮胎压力指示数据和确定表示轮胎中的轮胎压力偏差的轮胎压力偏差数据来检测车辆的轮胎中的轮胎压力偏差。

4. 发明申请

US20100143473A1 COMBINATION TREATMENT WITH STRONTIUM FOR THE PROPHYLAXIS AND/OR TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS 失效
标题翻译：用于治疗和/或治疗骨质疏松症和/或骨质疏松症的瘢痕组合治疗
公开(公告)号：US20100143473A1
公开(公告)日：2010-06-10
申请号：US12434971
申请日：2009-05-04
申请人： Christian Hansen , Henrik Nilsson , Stephan Christgau
发明人： Christian Hansen , Henrik Nilsson , Stephan Christgau
IPC分类号： A61K33/00 , A61K33/16 , A61K33/18 , A61K33/42 , A61K31/19 , A61K33/06 , A61K31/59 , A61K31/593 , A61K31/592 , A61K38/29 , A61P19/00 , A61K9/28
CPC分类号： A61K33/06 , A61K31/592 , A61K31/593 , A61K33/24 , A61K45/06 , A61K2300/00
摘要： A combination treatment, wherein a strontium-containing compound together with one or more active substances capable of reducing the incidence of bone fracture and/or increasing bone density and/or improving healing of fractured bone and/or improving bone quality are administered for use in the treatment and/or prophylaxis of cartilage and/or bone conditions.
摘要翻译：联合治疗，其中施用含锶化合物以及能够降低骨折发生率和/或增加骨密度和/或改善骨折骨愈合和/或改善骨质量的一种或多种活性物质用于治疗和/或预防软骨和/或骨骼状况。

5. 发明申请

US20080004344A1 Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use 审中-公开
标题翻译：富马酸单烷基酯的新型盐及其药物用途
公开(公告)号：US20080004344A1
公开(公告)日：2008-01-03
申请号：US11719052
申请日：2005-11-09
申请人： Henrik Nilsson , Jens Andersen , Bernd Mueller , Joseph Robinson , Bonna Robinson
发明人： Henrik Nilsson , Jens Andersen , Bernd Mueller , Joseph Robinson , Bonna Robinson
IPC分类号： A61K31/215 , A61P17/06 , A61P25/00 , A61P37/00 , C07C69/60
CPC分类号： C07C69/60 , C07C67/30
摘要： The present invention relates to novel strontium salts of fumaric acid monoalkylesters. The salts are suitable for use as active substances in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders either alone or in combination with another fumaric acid ester
摘要翻译：本发明涉及富马酸单烷基酯的新型锶盐。这些盐适合用作例如治疗中的活性物质。牛皮癣或其他过度增生，炎性或自身免疫性疾病，单独或与另一种富马酸酯组合

6. 发明申请

US20070037751A1 Uses of secretagogues like ghrelin in cancer cachexia and for stimulating appetite 审中-公开
标题翻译：使用促分泌素如生长素释放肽在癌症恶病质和刺激食欲
公开(公告)号：US20070037751A1
公开(公告)日：2007-02-15
申请号：US10567406
申请日：2004-08-06
申请人： Birgitte Lange , Christian Hansen , Henrik Nilsson
发明人： Birgitte Lange , Christian Hansen , Henrik Nilsson
IPC分类号： A61K38/08 , A61K38/05 , A61K38/06
CPC分类号： C07K14/575 , A61K38/00
摘要： The present invention relates, in one aspect, to the use of a secretagogue compound for the preparation of a medicament for the prophylaxis or treatment of cancer cachexia in an individual in need of such treatment. In another aspect, the present invention relates to the use of a ghrelin-like compound for the preparation of a medicament for prophylaxis or treatment of cachexia in an individual by administering a subcutaneous dosage of said medicament to the individual. In a further aspect, the present invention relates to the use of a ghrelin-like compound or a pharmaceutically acceptable salt thereof for the preparation of a medicament for stimulation of appetite in an individual by administering a subcutaneous dosage of said medicament to the individual. Furthermore, the present invention relates to a number of new ghrelin-like compounds and uses thereof, as well as to pharmaceutical compositions and medical packaging comprising the new ghrelin-like compounds.
摘要翻译：本发明在一个方面涉及促分泌素化合物在制备用于预防或治疗需要这种治疗的个体中的癌症恶病质的药物中的用途。另一方面，本发明涉及生长素释放肽样化合物在制备用于预防或治疗个体中恶病质的药物中的用途，其通过向个体施用皮下剂量的所述药物。在另一方面，本发明涉及生长素释放肽样化合物或其药学上可接受的盐在制备用于通过向个体施用所述药物的皮下剂量来刺激个体中的食欲的药物中的用途。此外，本发明涉及许多新的生长素释放肽样化合物及其用途，以及包含新的生长素释放肽样化合物的药物组合物和医药包装。

7. 发明授权

US09677488B2 Self-diagnosing method for diagnosing a SCR system 有权
公开(公告)号：US09677488B2
公开(公告)日：2017-06-13
申请号：US14390061
申请日：2012-04-10
申请人： Henrik Nilsson
发明人： Henrik Nilsson
IPC分类号： F01N3/00 , F02D41/02 , F01N3/20 , F01N11/00
CPC分类号： F02D41/0235 , F01N3/2066 , F01N11/00 , F01N11/007 , F01N2430/08 , F01N2550/02 , F01N2560/00 , F01N2560/026 , F01N2900/04 , F01N2900/1402 , F01N2900/1622 , Y02A50/2325 , Y02T10/24 , Y02T10/47
摘要： A self-diagnosing method for diagnosing a selective catalytic reduction (SCR) system of a vehicle that includes an internal combustion engine. An SCR system is arranged downstream of the engine, and the SCR system includes at least one exhaust gas sensor that is sensitive to nitrogen oxides (NOx) gas. The method includes a first diagnosing sequence (S1) of ensuring that the vehicle is in a stationary state, controlling the engine to operate in a high NOx output engine operating state and in a low NOx output engine operating state, registering an output signal of the at least one exhaust gas sensor when the engine operates in each of the high NOx output engine operating state and low NOx output engine operating state, and diagnosing NOx measurement performance of the at least one exhaust gas sensor on the basis of the registered sensor output.

8. 发明申请

US20110098556A1 Computer-Based Method And System For Imaging-Based Dynamic Function Evaluation Of An Organ 审中-公开
标题翻译：基于计算机的方法和系统，用于基于成像的一个器官的动态功能评估
公开(公告)号：US20110098556A1
公开(公告)日：2011-04-28
申请号：US12922152
申请日：2009-03-11
申请人： Lennart Blomqvist , Anders Nordell , Eduard Jonas , Henrik Nilsson
发明人： Lennart Blomqvist , Anders Nordell , Eduard Jonas , Henrik Nilsson
IPC分类号： A61B5/055
CPC分类号： G01R33/56366 , A61B5/42 , G01R33/485 , G01R33/5601 , G01R33/56308 , G16H50/20
摘要： A computer-based method of determining a functional assessment of at least one organ having secretional or excretional functions, such as a liver or kidneys, of a human is disclosed. The method comprises processing a four-dimensional (4D) image data set of said human comprising data for an assessment of said organ function, wherein said 4D image data is acquired by an image modality; and wherein said processing said 4D image data comprises performing a deconvolutional analysis (DA) comprising a matrix inversion using singular value decomposition (SVD) based on said 4D image data.
摘要翻译：公开了一种基于计算机的方法，其确定至少一个具有分泌或排泄功能的器官（例如肝或肾）的功能评估。该方法包括处理所述人的四维（4D）图像数据集合，其包括用于评估所述器官功能的数据，其中所述4D图像数据由图像模态获取; 并且其中所述处理所述4D图像数据包括基于所述4D图像数据执行包括使用奇异值分解（SVD）的矩阵求逆的解卷积分析（DA）。

9. 发明申请

US20090181887A1 USE OF A GLP-1 MOLECULE FOR TREATMENT OF BILIARY DYSKINESIA AND/OR BILIARY PAIN/DISCOMFORT 审中-公开
标题翻译：用于治疗胆汁淤积症和/或胆汁淤积/分泌的GLP-1分子的使用
公开(公告)号：US20090181887A1
公开(公告)日：2009-07-16
申请号：US12066178
申请日：2006-09-06
申请人： Christian Hansen , Henrik Nilsson , Hans T. Schambye , Tina Geritz Nielsen
发明人： Christian Hansen , Henrik Nilsson , Hans T. Schambye , Tina Geritz Nielsen
IPC分类号： A61K38/22 , A61P25/00 , G01N33/566
CPC分类号： A61K38/26 , G01N2333/605 , G01N2500/02 , G01N2800/08 , Y02A50/49
摘要： The present invention relates to molecules, compositions and methods suitable for the treatment or prevention of biliary dyskinesia and/or pain and/or discomfort originating from the biliary tree. The peptide hormone glucagon-like peptide-1 (GLP-1) has both anti-secretory effects and smooth muscle relaxatory properties in the gastrointestinal tract. GLP-1 exists in several forms, where the natural occurring GLP-1 molecules are GLP-1 (1-37), GLP-1 (7-37), and the amidated versions GLP-1 (1-36)amide, GLP-1 (7-36)amide. Other molecules capable of binding to and activating the GLP-1 receptor is herein included in the tern GLP-1 molecules. GLP-1 molecules may be naturally occurring or homologues of GLP-1 having one or more amino acid substitutions or modifications. The GLP-1 molecules are used for the manufacture of a medicament for the treatment or prevention of biliary dyskinesia and/or pain and/or discomfort originating from the biliary tree.
摘要翻译：本发明涉及适用于治疗或预防来自胆道树的胆汁运动障碍和/或疼痛和/或不适的分子，组合物和方法。肽激素胰高血糖素样肽-1（GLP-1）在胃肠道中具有抗分泌作用和平滑肌松弛性质。 GLP-1以几种形式存在，其中天然存在的GLP-1分子是GLP-1（1-37），GLP-1（7-37）和酰胺化型GLP-1（1-36）酰胺，GLP -1（7-36）酰胺。在GLP-1分子中包括能够结合并激活GLP-1受体的其它分子。 GLP-1分子可以是具有一个或多个氨基酸取代或修饰的GLP-1的天然存在或同源物。 GLP-1分子用于制造用于治疗或预防胆汁运动障碍和/或来自胆道树的疼痛和/或不适的药物。

10. 发明申请

US20060122274A1 Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions 失效
公开(公告)号：US20060122274A1
公开(公告)日：2006-06-08
申请号：US11269289
申请日：2005-11-07
申请人： Christian Hansen , Henrik Nilsson , Stephan Christgau , Jens Andersen
发明人： Christian Hansen , Henrik Nilsson , Stephan Christgau , Jens Andersen
IPC分类号： A61K31/198 , C07F3/02
CPC分类号： A61K33/24 , C07C55/08 , C07C55/10 , C07C57/145 , C07C59/08 , C07C59/19 , C07C59/347
摘要： Compounds and pharmaceutical compositions for use in the treatment and/or prophylaxis of cartilage and/or bone conditions and for methods of treating such condition. The compounds are salts of strontium that have a water-solubility of from about 1 g/l to about 100 g/l at room temperature, especially amino acid salts of strontium or dicarboxylic acid salts of strontium. Examples of novel water-soluble strontium salts are e.g. strontium glutamate and strontium alpha-ketoglutarate. The present invention also relates to an improved method for preparing the strontium salt of glutamic acid.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式